Please Upload related files below
Fill in below.
Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery - link your account with SnapTrade.
XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint. Specifically, the Company noted that “substantial irregularities that make unequivocal interpretation of the findings difficult.”
Following this news, XBiotech’s stock price sharply fell during intraday trading on the same day.